Article Text

Download PDFPDF
410 Tumor immune microenvironment and high grade serous ovarian carcinoma: immunophenotyping of tumor-infiltrating B cells
  1. Martina Arcieri1,2,
  2. Eleonora Capezzali3,
  3. Stefano Restaino1,
  4. Laura Mariuzzi4,
  5. Maria Orsaria5,
  6. Angelica Tulisso5,
  7. Giulia Pellecchia6,
  8. Rita Trozzi7,
  9. Camilla Nero8,9,
  10. Lorenza Driul1,6,
  11. Giovanni Scambia8,9,
  12. Alfredo Ercoli10,
  13. Silvia Tonon3,
  14. Carlo Pucillo3,
  15. Barbara Frossi3 and
  16. Giuseppe Vizzielli1,6
  1. 1Department of Maternal and Child Health, ‘Santa Maria della Misericordia’ University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
  2. 2Department of Biomedical, Dental, Morphological and Functional Imaging Science, University of Messina, Messina, Italy
  3. 3Department of Medicine, University of Udine, Udine, Italy
  4. 4Institute of Pathology, DAME, University of Udine, Udine, Italy
  5. 5Institute of Pathology, Academic Hospital, Udine, Italy
  6. 6Medical Area Department (DAME), University of Udine, Udine, Italy
  7. 7Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, Rome, Italy
  8. 8Department of Woman, Children and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  9. 9Institute of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
  10. 10Obstetrics and Gynecology Unit, Department of Human Pathology of Adult and Childhood ‘G. Baresi’, University Hospital ‘G. Martino’, Messina, Italy


Introduction/Background Emerging evidence underscore the critical involvement of B cells in ovarian cancer pathogenesis. B cells infiltrating the tumor microenvironment (TME) display both pro- and anti- tumorigenic activities. However, currently, there is no validated panel for analyzing tumor-infiltrating B cells by cytofluorimetry. We developed a high dimensional approach for the wide characterization of the tumor immune infiltrate and optimized a specific panel for the immunophenotyping of B cell subpopulations in both peripheral blood and TME. The objectives of this study were to evaluate TME in patients with high grade serous ovarian cancer (HGSOC) and specifically assessing the role of B cells in peritoneal biopsies by flowcytometry.

Methodology This prospective observational study was conducted at University Hospital of Udine. Patients with advanced HGSOC were recruited. Cells obtained from peritoneal biopsies, were analyzed by cytofluorimetry.

Results 13 patients were enrolled. We designed a specific panel to analyze B cells in peritoneal biopsies of HGSOC patients by flowcytometry (figure 1). In our analysis, the proportion of immune cells CD45+ ranged from 0.77% to 98% of viable cells while of B cells varied from 0.70% to 28.6%. Among the B cells, the proportion of double negative cells (CD27-/IgD-) ranged from 31.3% to 66.8%. We also analyzed data of peritoneal biopsies of one patient before and after 3 cycles of neoadjuvant chemotherapy. The immune infiltrate increased from 24.6% to 59.8% while the percentages of B cell decreased (6.67% to 3.74%) with a concomitant increase of activated B cell (from 55% to 85.1%) and memory switched B cells (26.9% to 42.5%).

Conclusion It is the first study that developed an expanded panel to analyze the subpopulations of B cells in peritoneal biopsies of HGSOC patients by cytofluorimetry. Better knowledge of TME could tailor the management of HGSOC to the unique characteristics of the patient‘s tumor.

Disclosures Authors declare to have no disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.